Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study

Information processing speed in multiple sclerosis: Past, present, and future

(2016) Silvana L Costa et al.   Multiple Sclerosis Journal

Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients

(2016) Niels Bergsland et al.   Multiple Sclerosis Journal

Information processing speed in multiple sclerosis: Past, present, and future

(2016) Silvana L Costa et al.   Multiple Sclerosis Journal

Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients

(2016) Niels Bergsland et al.   Multiple Sclerosis Journal

Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab

(2016) Malte Roar et al.   Multiple Sclerosis and Related Disorders

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis

(2015) Ludwig Kappos et al.   JOURNAL OF NEUROLOGY

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2015) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial

(2014) Naghmeh Mokhber et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Characterizing cognitive function during relapse in multiple sclerosis

(2014) Ralph HB Benedict et al.   Multiple Sclerosis Journal

Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis

(2013) Heinz Wiendl et al.   Nature Reviews Neurology

The thalamus and multiple sclerosis: Modern views on pathologic, imaging, and clinical aspects

(2013) A. Minagar et al.   NEUROLOGY

Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study

(2013) Francesco Patti et al.   PLoS One

Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials

(2012) Ralph HB Benedict et al.   Multiple Sclerosis Journal

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS

(2011) Bianca Weinstock-Guttman et al.   JOURNAL OF NEUROLOGY

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

(2011) DW Langdon et al.   Multiple Sclerosis Journal

Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline

(2010) Sarah A. Morrow et al.   CLINICAL NEUROPSYCHOLOGIST

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

(2010) SA Morrow et al.   Multiple Sclerosis Journal

The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study

(2010) Flavia Mattioli et al.   NEUROLOGICAL SCIENCES

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

(2009) F. Patti et al.   Multiple Sclerosis Journal